Skip to Main Content

Syros Pharmaceuticals and Global Blood Therapeutics on Wednesday announced a research alliance to discover and develop new drugs, potentially oral medicines, to treat the inherited blood disorders sickle cell disease and beta-thalassemia.

Under the agreement, Cambridge, Mass.-based Syros scientists will use genomic analysis to identify proteins called transcription factors that turn on, or off, genes related to the production of fetal hemoglobin.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!